The Biostatistics Core facility provides the statistical design, data management, and computational support for all Leukemia SPORE investigators. The Core will support consultation and collaboration on all aspects of study design, database development and quality control, and analysis and interpretation of data. The statisticians participating in the Biostatistics Core bring established collaborations and a broad range of expertise and experience in clinical trials, laboratory experiments, genetics and genomics research, and epidemiology studies. Dr. Graham Colditz, Katherine Trinkaus, and Feng Gao, have extensive experience as investigators and statisticians within the Hematopoietic Development and Malignancy Program at Siteman. Dr. Petti brings bioinformatics expertise and a record of collaboration with Drs. Welch and Ley. The team brings expertise in monitoring minority accrual, OnCore, REDCap and data management/analysis for clinical studies. Collectively, these individuals have affiliations at Washington University School of Medicine and the Siteman Cancer Center. The Biostatistics Core members have participated regularly in the investigator meetings for the SPORE projects over the past 5 years and in design of developmental projects and career enrichment program where they provide support and training for junior investigators.
The specific aims of this core are to; 1: Provide biostatistical and bioinformatics collaboration for Projects, Developmental Research program and Cores in the SPORE, to assure robust statistical methods support the projects; 2: Provide biostatistical and bioinformatics support and training to junior investigators through the CEP.

Public Health Relevance

During recent decades, the development and application of new statistical methodology for cancer research has resulted in an expanded role for statisticians. The Biostatistics Core provides the statistical, bioinformatics, and computational support for all Leukemia SPORE investigators. The Core will support consultation and collaboration on all aspects of study design, database development and quality control, and analysis, interpretation, and presentation of data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA171963-08
Application #
9961534
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Trissal, Maria C; Wong, Terrence N; Yao, Juo-Chin et al. (2018) MIR142 Loss-of-Function Mutations Derepress ASH1L to Increase HOXA Gene Expression and Promote Leukemogenesis. Cancer Res 78:3510-3521
Jacoby, Meagan A; Duncavage, Eric J; Chang, Gue Su et al. (2018) Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight 3:
Monlish, Darlene A; Bhatt, Sima T; Duncavage, Eric J et al. (2018) Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the NUP98-HOXD13 mouse model of MDS. Blood 131:1032-1035
Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494
Staser, Karl W; Eades, William; Choi, Jaebok et al. (2018) OMIP-042: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood. Cytometry A 93:186-189
Warner, Wayne A; Spencer, David H; Trissal, Maria et al. (2018) Expression profiling of snoRNAs in normal hematopoiesis and AML. Blood Adv 2:151-163
Nguyen, Hai Dang; Leong, Wan Yee; Li, Weiling et al. (2018) Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes. Cancer Res 78:5363-5374
Cooper, Matthew L; Choi, Jaebok; Staser, Karl et al. (2018) An ""off-the-shelf"" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 32:1970-1983
Wang, Tianjiao; Jacoby, Meagan A; Duncavage, Eric J et al. (2018) Exome analysis of treatment-related AML after APL suggests secondary evolution. Br J Haematol :
Bansal, Dhruv; Vij, Kiran; Chang, Gue Su et al. (2018) Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. Haematologica 103:e270-e273

Showing the most recent 10 out of 64 publications